Physalin A modulated the tyrosine phosphorylation of JAK2 and JAK3 in a dose-dependent manner and abrogated the nuclear translocation and transcriptional activity of STAT3, showing anticancer activity in NSCLC [200]. The gene discussed is JAK2; the disease is non-small cell lung carcinoma.